Coogan- P F, Rosenberg L, Palmer J R, Strom B L, Stolley P D, Zauber A G, Shapiro S
Slone Epidemiology Unit, Boston University school of Medicine, Brookline, MA 02446, USA.
Cancer Causes Control. 2000 Oct;11(9):839-45. doi: 10.1023/a:1008982417022.
An association of increased risk of ovarian cancer with use of antidepressants or benzodiazepine tranquilizers has been reported from a case-control study. We assessed the association between ovarian cancer risk and the use of tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), phenothiazine antipsychotics, and benzodiazepines, in data from the Case-Control Surveillance Study.
From 1976 through 1998, data were collected from hospital patients in Boston, New York, Philadelphia, and Baltimore based on demographic factors, reproductive and medical history, and medication use. In the present analyses, cases of epithelial ovarian cancer (n = 748) were compared with cancer controls (n = 1496) and noncancer controls admitted for trauma and acute infection (n = 1496). We estimated Mantel-Haenszel odds ratios adjusted for age, study center, and year of interview.
Odds ratios for regular use (at least 4 days/week for at least 1 month) were compatible with 1.0 for every drug class. For tricyclics and benzodiazepines the upper 95% confidence limits were less than 1.6. For phenothiazines the upper limit was 2.6 with cancer controls and 1.4 with noncancer controls. Only five cases used SSRIs, yielding unstable results. Odds ratios were not increased among women who had used any drug class for at least 5 years, nor among women who had first used them 10 or more years previously.
These data do not support an association between regular use of any of the drugs under study with ovarian cancer risk.
一项病例对照研究报告称，使用抗抑郁药或苯二氮䓬类镇静剂会增加患卵巢癌的风险。我们在病例对照监测研究的数据中，评估了卵巢癌风险与使用三环类抗抑郁药、选择性5-羟色胺再摄取抑制剂（SSRI）、吩噻嗪类抗精神病药和苯二氮䓬类药物之间的关联。
1976年至1998年期间，收集了波士顿、纽约、费城和巴尔的摩医院患者的人口统计学因素、生殖和病史以及用药情况等数据。在本次分析中，将上皮性卵巢癌患者（n = 748）与癌症对照者（n = 1496）以及因创伤和急性感染入院的非癌症对照者（n = 1496）进行了比较。我们估计了经年龄、研究中心和访谈年份调整后的曼特尔-亨塞尔优势比。
每种药物类别常规使用（至少每周4天，持续至少1个月）的优势比均与1.0相符。对于三环类药物和苯二氮䓬类药物，95%置信区间上限小于1.6。对于吩噻嗪类药物，与癌症对照者比较时上限为2.6，与非癌症对照者比较时上限为1.4。仅5例患者使用了SSRI，结果不稳定。在使用任何药物类别至少5年的女性中，以及在首次使用药物10年或更早以前的女性中，优势比均未升高。
这些数据不支持常规使用所研究的任何药物与卵巢癌风险之间存在关联。
